Inventiva (NASDAQ:IVA) Now Covered by HC Wainwright

Key Points

• Inventiva (NASDAQ:IVA) received a "buy" rating from HC Wainwright, with a price target of $20.00, indicating a potential upside of 280.23% from its current price.
• Current analyst ratings show a consensus of five "buy" ratings and one "hold" rating, with an average target price of $14.83 according to MarketBeat.com.
• Inventiva specializes in developing oral small molecule therapies for conditions like non-alcoholic steatohepatitis (NASH), with its lead product candidate, Lanifibranor, currently in Phase III clinical trials.

Stock analysts at HC Wainwright initiated coverage on shares of Inventiva (NASDAQ:IVA - Get Free Report) in a research note issued on Wednesday, MarketBeat reports. The firm set a "buy" rating and a $20.00 price target on the stock. HC Wainwright's price objective points to a potential upside of 269.34% from the company's current price. HC Wainwright also issued estimates for Inventiva's FY2025 earnings at ($1.44) EPS, FY2026 earnings at ($1.66) EPS, FY2027 earnings at ($2.43) EPS, FY2028 earnings at $0.49 EPS and FY2029 earnings at $3.19 EPS.

IVA has been the topic of several other reports. Guggenheim lifted their price target on shares of Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Piper Sandler started coverage on shares of Inventiva in a research note on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $14.83.

Inventiva Price Performance

Shares of NASDAQ:IVA traded down $0.16 during midday trading on Wednesday, hitting $5.42. The stock had a trading volume of 36,936 shares, compared to its average volume of 23,178. The company's 50-day moving average price is $3.90 and its 200-day moving average price is $3.48. Inventiva has a fifty-two week low of $1.53 and a fifty-two week high of $6.50.

Hedge Funds Weigh In On Inventiva

A hedge fund recently raised its stake in Inventiva stock. Wealth Enhancement Advisory Services LLC boosted its position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,558 shares of the company's stock after acquiring an additional 5,843 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 as of its most recent SEC filing. Institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.